Stress Response Pathways in Vitiligo

Identifying a role for NF-κB signaling in vitiligo may improve therapies for this disfiguring
disorder. Current treatments vary in effectiveness and may not always be long lasting cases.
The NF-κB pathway and IL-6 itself are the target of several FDA approved drugs, thus opening
new therapeutic avenues.

Inclusion Criteria:

- To be eligible for participation, subjects must meet all of the following criteria:

- Must have a clinical exam consistent with and diagnosis of non-segmental vitiligo

- Must be normally pigmented

- No clinical presentation of vitiligo

Exclusion Criteria:

- Outside of the specified age range

- No clinical diagnosis of vitiligo

- Use of systemic therapies, including but not limited to methotrexate, etretinate, or
cyclosporine, calcineurin inhibitors and/ or vitamin D analogs within 4 weeks of
enrollment

- Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of
enrollment

- History of keloids or hypertrophic scars

- Patients with pacemakers or defibrillators or heart valves

- Patients on Plavix, Warfarin or similar anticoagulation medicine

- Pregnant females

- Lactating women

- Allergies or sensitivity to lidocaine or epinephrine

- Outside of the specified age range

- Abnormally pigmented at potential biopsy sites (non-vitiligo)

- Clinical presentation of vitiligo

- Use of systemic therapies, including but not limited to methotrexate, etretinate, or
cyclosporine, calcineuron inhibitors and/ or vitamin D analogs within 4 weeks of
enrollment

- Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of
enrollment

- History of keloids or hypertrophic scars